Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jocelyn Rivera is active.

Publication


Featured researches published by Jocelyn Rivera.


ACS Medicinal Chemistry Letters | 2010

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

Kamil Paruch; Michael P. Dwyer; Carmen Alvarez; Courtney Brown; Tin-Yau Chan; Ronald J. Doll; Kerry Keertikar; Chad E. Knutson; Brian Mckittrick; Jocelyn Rivera; Randall R. Rossman; Greg Tucker; Thierry O. Fischmann; Alan Hruza; Vincent Madison; Amin A. Nomeir; Yaolin Wang; Paul Kirschmeier; Emma Lees; David Parry; Nicole Sgambellone; Wolfgang Seghezzi; Lesley Schultz; Frances Shanahan; Derek Wiswell; Xiaoying Xu; Quiao Zhou; Ray Anthony James; Vidyadhar M. Paradkar; Haengsoon Park

Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.


Tetrahedron Letters | 2002

Synthesis of substituted 1H-imidazol-1-ylmethylpiperidines. Facile separation of 1,4- and 1,5-disubstituted imidazoles

Jocelyn Rivera; Nilukshi Jayasuriya; Dinanath F. Rane; Kerry Keertikar; J. Albert Ferreira; Jiangping Chao; Keith P. Minor; Timothy J. Guzi

The synthesis of several 1H-imidazol-1-ylmethylpiperidines is described. A method for the regioselective isolation of 1,4-disubstituted imidazoles utilizing the selective quaternization of the 1,5-disubstituted regioisomer was developed.


Archive | 2002

17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Timothy J. Guzi; Kamil Paruch; Alan K. Mallams; Jocelyn Rivera; Ronald J. Doll; Viyyoor M. Girijavallabhan; Jonathan A. Pachter; Yi-Tsung Liu; Anil K. Saksena


Bioorganic & Medicinal Chemistry Letters | 2007

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2

Kamil Paruch; Michael P. Dwyer; Carmen Alvarez; Courtney Brown; Tin-Yau Chan; Ronald J. Doll; Kerry Keertikar; Chad E. Knutson; Brian Mckittrick; Jocelyn Rivera; Randall R. Rossman; Greg Tucker; Thierry O. Fischmann; Alan Hruza; Vincent Madison; Amin A. Nomeir; Yaolin Wang; Emma Lees; David Parry; Nicole Sgambellone; Wolfgang Seghezzi; Lesley Schultz; Fran Shanahan; Derek Wiswell; Xiaoying Xu; Quiao Zhou; Ray Anthony James; Vidyadhar M. Paradkar; Haengsoon Park; Laura R. Rokosz


Archive | 2005

Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors

Timothy J. Guzi; Kamil Paruch; Michael P. Dwyer; Ronald J. Doll; Viyyoor M. Girijavallabhan; Alan K. Mallams; Carmen Alvarez; Kartik M. Keertikar; Jocelyn Rivera; Tin-Yau Chan; Vincent Madison; Thierry O. Fischmann; Lawrence W. Dillard; Vinh D. Tran; Zhen Min He; Ray Anthony James; Haengsoon Park; Vidyadhar M. Paradkar; Douglas W. Hobbs


Archive | 2006

N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

Timothy J. Guzi; Kamil Paruch; Michael P. Dwyer; Ronald J. Doll; Viyyoor M. Girijavallabhan; Alan K. Mallams; Carmen Alvarez; Kartik M. Keertikar; Jocelyn Rivera; Tin Yau Chan; Vincent Madison; Thierry O. Fischmann; Lawrence W. Dillard; Vinh D. Tran; Zhen Min He; Ray Anthony James; Haengsoon Park; Vidyadhar M. Paradkar; Douglas W. Hobbs


Archive | 2013

PYRAZOLOPYRIMIDINES - DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS

Timothy J. Guzi; Madison Vincent S; Tin-Yau Chan; Vincent S. Madison; Fischmann Thierry O; Dillard Lawrence W; Tran Vinh D; Min He Zhen; Anthony James Ray; Haengsoon Park; Paradkar Vidyadhar M; Kamil Paruch; Walsh Hobbs Douglas; Dwyer Michael P; Doll Ronald J; Moopil Girijavallabhan Viyyoor; Alan K. Mallams; Alvarez Carmen S; Keertikar Kartik M; Jocelyn Rivera


Archive | 2010

Zur Behandlung von Krebserkrankungen geeignete Pyrazolopyrimidine

Timothy J. Guzi; Kamil Paruch; Michael P. Dwyer; Ronald J. Doll; Viyyoor M. Girijavallabhan; Alan K. Mallams; Carmen Alvarez; Kartik M. Keertikar; Jocelyn Rivera; Tin-Yau Chan; Vincent S. Madison; Thierry O. Fischmann; Lawrence W. Dillard; Vinh D. Tran; Zhen Min He; Ray Anthony James; Haengsoon Park; Vidyadhar M. Paradkar; Douglas W. Hobbs


Archive | 2010

Pyrazolopyrimidine derivative as cyclin dependent kinase inhibitor

Carmen Alvarez; Tin-Yau Chan; Lawrence W. Dillard; Ronald J. Doll; Michael P. Dwyer; Thierry O. Fischmann; Viyyoor M. Girijavallabhan; Timothy J. Guzi; Zhen Min He; Douglas W. Hobbs; Ray Anthony James; Kartik M. Keertikar; Vincent S. Madison; Alan K. Mallams; Vidyadhar M. Paradkar; Haengsoon Park; Kamil Paruch; Jocelyn Rivera; Vinh D. Tran; マラムス アラン; パルチ カミル; エム. キールティカール カルティック; エス. アルバレス カルメン; リベラ ジョセリン; ウォルシュ ホッブス ダグラス; ミン ホー チェン; ティン−ヤウ チャン; オー. フィッシュマン ティエリー; ジェイ. グジ ティモシー; エム. パラドカル ビドヤドハー


Archive | 2008

Nouveaux pyrazolopyrimidines utilisés comme inhibiteurs des kinases dépendants des cyclines

Timothy J. Guzi; Kamil Paruch; Michael P. Dwyer; Ronald J. Doll; Viyyoor M. Girijavallabhan; Alan K. Mallams; Carmen Alvarez; Kartik M. Keertikar; Jocelyn Rivera; Tin-Yau Chan; Vincent S. Madison; Thierry O. Fischmann; Paul Kirschmeier; Rajat Bannerji; Lawrence W. Dillard; Vinh D. Tran; Zhenmin He; Ray Anthony James; Haengsoon Park; Vidyadhar M. Paradkar; Douglas W. Hobbs

Collaboration


Dive into the Jocelyn Rivera's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge